INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is characterized by a progressive bronchial obstruction, and bronchodilators represent the maintenance therapeutic choice. Tiotropium is an anticholinergic drug that is proved to be safe, efficient and simple to handle; Respimat® technology was recently introduced as a new device for tiotropium administration. AREAS COVERED: This paper reviews clinical trials and meta-analyses, with tiotropium efficacy as a primary end point, found in MedLine, the Cochrane trials database and Embase. Only the literature published after the UPLIFT study has been considered. EXPERT OPINION: Data published after the UPLIFT study confirms the efficacy of tiotropium as maintenance COPD therapy and its capacity to reduce airflow obstruction, as well as lung hyperinflation. Nevertheless, there is a certain inhomogeneity in the definition and evaluation of COPD exacerbations, in lung functional parameters and quality-of-life assessment, and there has not always been a proper comparison between tiotropium and other long-acting bronchodilators. Respimat is comparable in efficacy to the HandiHaler®, using bioequivalent doses of tiotropium.
Tiotropium: what came after the UPLIFT study / P. Santus, F. Di Marco, D. Radovanovic, S. Centanni. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 13:4(2012 Mar), pp. 613-618.
|Titolo:||Tiotropium: what came after the UPLIFT study|
SANTUS, PIERACHILLE (Primo)
DI MARCO, FABIANO (Secondo)
CENTANNI, STEFANO (Ultimo)
|Parole Chiave:||anticholinergic ; COPD ; outcome ; respimat ; tiotropium|
|Settore Scientifico Disciplinare:||Settore MED/10 - Malattie dell'Apparato Respiratorio|
|Data di pubblicazione:||mar-2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1517/14656566.2012.656592|
|Appare nelle tipologie:||01 - Articolo su periodico|